{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:04:10Z","timestamp":1793711050381,"version":"4.6.1"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.seizure.2022.03.024","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T01:53:20Z","timestamp":1649037200000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Molecular mechanisms of topiramate and its clinical value in epilepsy"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-3110","authenticated-orcid":false,"given":"Yun-Fei","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10172","key":"10.1016\/j.seizure.2022.03.024_bib0001","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.mcna.2018.10.002","article-title":"Seizures and epilepsy","volume":"103","author":"Johnson","year":"2019","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.seizure.2022.03.024_bib0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/B978-0-444-64148-9.00011-9","volume":"174","author":"Bastos","year":"2020","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0004","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nn.3947","article-title":"Molecular mechanisms of epilepsy","volume":"18","author":"Staley","year":"2015","journal-title":"Nat Neurosci"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0005","article-title":"Pediatric epilepsy mechanisms: expanding the paradigm of excitation\/inhibition imbalance","volume":"6","author":"Shao","year":"2019","journal-title":"Children (Basel)"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0006","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/pr.117.014456","article-title":"Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies","volume":"70","author":"Oyrer","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0007","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12264-017-0134-1","article-title":"Ion channel genes and epilepsy: functional alteration, pathogenic potential, and mechanism of epilepsy","volume":"33","author":"Wei","year":"2017","journal-title":"Neurosci Bull"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0008","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3988\/jcn.2020.16.3.383","article-title":"Refining general principles of antiepileptic drug treatments for epilepsy","volume":"16","author":"Kim","year":"2020","journal-title":"J Clin Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0009","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1474-4422(21)00023-5","article-title":"Epilepsy in China: major progress in the past two decades","volume":"20","author":"Ding","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0010","first-page":"508","article-title":"Update on antiepileptic drugs","volume":"25","author":"Abou-Khalil","year":"2019","journal-title":"Continuum (Minneap Minn) 2019"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0011","first-page":"811","article-title":"Topiramate in the treatment of partial and generalized epilepsy","volume":"3","author":"Faught","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0012","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1517\/14656566.7.6.811","article-title":"Topiramate and its clinical applications in epilepsy","volume":"7","author":"Guerrini","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/138955708783331568","article-title":"Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy","volume":"8","author":"Latini","year":"2008","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0014","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11096-018-0641-9","article-title":"Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses","volume":"40","author":"Campos","year":"2018","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/WNF.0000000000000200","article-title":"Efficacy of treatments for infantile spasms: a systematic review","volume":"40","author":"Song","year":"2017","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2022.03.024_bib0016","article-title":"Topiramate add-on therapy for drug-resistant focal epilepsy","volume":"10","author":"Bresnahan","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0017","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.braindev.2020.08.015","article-title":"Clinical characteristics of KCNQ2 encephalopathy","volume":"43","author":"Kim","year":"2021","journal-title":"Brain Dev"},{"issue":"5","key":"10.1016\/j.seizure.2022.03.024_bib0018","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ajhg.2018.09.006","article-title":"De novo pathogenic variants in CACNA1E cause developmental and epileptic encephalopathy with contractures, macrocephaly, and dyskinesias","volume":"103","author":"Helbig","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"42","key":"10.1016\/j.seizure.2022.03.024_bib0019","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.2174\/1381612823666171115101557","article-title":"Seizures and antiepileptic drugs: from pathophysiology to clinical practice","volume":"23","author":"Carcak","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.seizure.2022.03.024_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","author":"Hansen","year":"2018","journal-title":"Behav Neurol 2018"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0021","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/1060028014557859","article-title":"Pharmacological management of obesity in pediatric patients","volume":"49","author":"Boland","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0022","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/head.12826","article-title":"Topiramate for treatment in patients with migraine and epilepsy","volume":"56","author":"Spritzer","year":"2016","journal-title":"Headache"},{"issue":"5","key":"10.1016\/j.seizure.2022.03.024_bib0023","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2022.03.024_bib0024","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/bs.podrm.2018.11.005","article-title":"Topiramate: comprehensive profile","volume":"44","author":"Khalil","year":"2019","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"15","key":"10.1016\/j.seizure.2022.03.024_bib0025","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","article-title":"Topiramate: a review of its use in the treatment of epilepsy","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0026","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022814","article-title":"Role of sodium channels in epilepsy","volume":"6","author":"Kaplan","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.seizure.2022.03.024_bib0027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpn.2019.12.009","article-title":"Recent advances in treatment of epilepsy-related sodium channelopathies","volume":"24","author":"Musto","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2022.03.024_bib0028","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fphar.2020.01276","article-title":"Epilepsy-related voltage-gated sodium channelopathies: a review","volume":"11","author":"Menezes","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seizure.2022.03.024_bib0029","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","article-title":"From genotype to phenotype in Dravet disease","volume":"44","author":"Gataullina","year":"2017","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12883-021-02395-2","article-title":"Response to sodium channel blocking antiseizure medications and coding polymorphisms of sodium channel genes in taiwanese epilepsy patients","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0031","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1528-1167.2007.01001.x","article-title":"Carbamazepine and topiramate modulation of transient and persistent sodium currents studied in HEK293 cells expressing the Na(v)1.3 alpha-subunit","volume":"48","author":"Sun","year":"2007","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2022.03.024_bib0032","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1528-1167.2011.03046.x","article-title":"Therapy for hyperthermia-induced seizures in Scn1a mutant rats","volume":"52","author":"Hayashi","year":"2011","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0033","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022723","article-title":"The role of calcium channels in epilepsy","volume":"6","author":"Rajakulendran","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"10.1016\/j.seizure.2022.03.024_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092735","article-title":"Voltage-dependent calcium channels, calcium binding proteins, and their interaction in the pathological process of epilepsy","volume":"19","author":"Xu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seizure.2022.03.024_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1874205X01610010099","article-title":"Review: cav2.3 R-type voltage-gated Ca(2+) channels - functional implications in convulsive and non-convulsive seizure activity","volume":"10","author":"Wormuth","year":"2016","journal-title":"Open Neurol J"},{"issue":"S1","key":"10.1016\/j.seizure.2022.03.024_bib0036","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","article-title":"Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate","volume":"41","author":"Zhang","year":"2000","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0037","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.0013-9580.2005.35304.x","article-title":"Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels","volume":"46","author":"Kuzmiski","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.03.024_bib0038","article-title":"Rational approaches for the design of various GABA modulators and their clinical progression","author":"Bhagat","year":"2020","journal-title":"Mol Divers"},{"issue":"8","key":"10.1016\/j.seizure.2022.03.024_bib0039","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dmcn.14152","article-title":"Gene mutations in paediatric epilepsies cause NMDA-pathy, and phasic and tonic GABA-pathy","volume":"61","author":"Gataullina","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.seizure.2022.03.024_bib0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neubiorev.2015.12.014","article-title":"GABA-ergic cell therapy for epilepsy: advances, limitations and challenges","volume":"62","author":"Shetty","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0041","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.neulet.2010.09.033","article-title":"Up-regulation of GABA transporters and GABA(A) receptor alpha1 subunit in tremor rat hippocampus","volume":"486","author":"Mao","year":"2010","journal-title":"Neurosci Lett"},{"issue":"5","key":"10.1016\/j.seizure.2022.03.024_bib0042","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.neuron.2015.03.042","article-title":"The GABAA receptor as a therapeutic target for neurodevelopmental disorders","volume":"86","author":"Braat","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.seizure.2022.03.024_bib0043","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.brainres.2019.03.004","article-title":"A structural look at GABAA receptor mutations linked to epilepsy syndromes","volume":"1714","author":"Hernandez","year":"2019","journal-title":"Brain Res"},{"issue":"S1","key":"10.1016\/j.seizure.2022.03.024_bib0044","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","article-title":"Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism","volume":"41","author":"White","year":"2000","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1528-1157.2001.18800.x","article-title":"Topiramate rapidly raises brain GABA in epilepsy patients","volume":"42","author":"Petroff","year":"2001","journal-title":"Epilepsia"},{"issue":"S1","key":"10.1016\/j.seizure.2022.03.024_bib0046","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1528-1157.2000.tb02167.x","article-title":"Differential sensitivity of recombinant GABA(A) receptors expressed in Xenopus oocytes to modulation by topiramate","volume":"41","author":"Gordey","year":"2000","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2022.03.024_bib0047","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.neuropharm.2005.12.006","article-title":"Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors","volume":"50","author":"Simeone","year":"2006","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.seizure.2022.03.024_bib0048","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022863","article-title":"Glutamatergic mechanisms associated with seizures and epilepsy","volume":"5","author":"Barker-Haliski","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030464","article-title":"Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0050","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s13760-020-01318-1","article-title":"Molecular insights into the role of AMPA receptors in the synaptic plasticity, pathogenesis and treatment of epilepsy: therapeutic potentials of perampanel and antisense oligonucleotide (ASO) technology","volume":"120","author":"Charsouei","year":"2020","journal-title":"Acta Neurol Belg"},{"issue":"S1","key":"10.1016\/j.seizure.2022.03.024_bib0051","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","article-title":"Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons","volume":"41","author":"Gibbs","year":"2000","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0052","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1471-4159.2003.02186.x","article-title":"Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level","volume":"88","author":"Angehagen","year":"2004","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0053","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","article-title":"Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures","volume":"94","author":"Angehagen","year":"2005","journal-title":"J Neurochem"},{"issue":"19","key":"10.1016\/j.seizure.2022.03.024_bib0054","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/0024-3205(96)00492-4","article-title":"Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER)","volume":"59","author":"Kanda","year":"1996","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0055","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1166\/jbn.2013.1599","article-title":"A comparison of extracellular excitatory amino acids release inhibition of acute lamotrigine and topiramate treatment in the hippocampus of PTZ-kindled epileptic rats","volume":"9","author":"Deng","year":"2013","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.seizure.2022.03.024_bib0056","first-page":"1","article-title":"An overview of carbohydrate-based carbonic anhydrase inhibitors","author":"Cuffaro","year":"2020","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.seizure.2022.03.024_bib0057","article-title":"Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors","author":"Kumar","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0058","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/13543776.2013.782394","article-title":"Anticonvulsant\/antiepileptic carbonic anhydrase inhibitors: a patent review","volume":"23","author":"Aggarwal","year":"2013","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.seizure.2022.03.024_bib0059","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.neuropharm.2015.04.015","article-title":"Carbonic anhydrase inhibition by acetazolamide reduces in vitro epileptiform synchronization","volume":"95","author":"Hamidi","year":"2015","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.seizure.2022.03.024_bib0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/13543776.2018.1519023","article-title":"Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases","volume":"28","author":"Supuran","year":"2018","journal-title":"Expert Opin Ther Pat"},{"issue":"S1","key":"10.1016\/j.seizure.2022.03.024_bib0061","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1157.2000.tb02169.x","article-title":"Topiramate as an inhibitor of carbonic anhydrase isoenzymes","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0062","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bmcl.2004.12.052","article-title":"Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides","volume":"15","author":"Vullo","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"issue":"16","key":"10.1016\/j.seizure.2022.03.024_bib0063","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/cmdc.201500596","article-title":"In vivo evaluation of selective carbonic anhydrase inhibitors as potential anticonvulsant agents","volume":"11","author":"Bruno","year":"2016","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0064","first-page":"557","article-title":"Neuroprotective effects of antiepileptic drugs","volume":"54","author":"Trojnar","year":"2002","journal-title":"Pol J Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0065","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1124\/jpet.103.057091","article-title":"Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy","volume":"308","author":"Rigoulot","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0066","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5114\/fn.2019.88456","article-title":"Effects of topiramate on the ultrastructure of synaptic endings in the hippocampal CA1 and CA3 sectors in the rat experimental model of febrile seizures: the first electron microscopy report","volume":"57","author":"Lotowska","year":"2019","journal-title":"Folia Neuropathol"},{"key":"10.1016\/j.seizure.2022.03.024_bib0067","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2016.04.036","article-title":"Involvement of AMPA\/kainate and GABAA receptors in topiramate neuroprotective effects against methylphenidate abuse sequels involving oxidative stress and inflammation in rat isolated hippocampus","volume":"784","author":"Motaghinejad","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.seizure.2022.03.024_bib0068","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00702-017-1771-2","article-title":"Topiramate via NMDA, AMPA\/kainate, GABAA and Alpha2 receptors and by modulation of CREB\/BDNF and Akt\/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats","volume":"124","author":"Motaghinejad","year":"2017","journal-title":"J Neural Transm (Vienna"},{"key":"10.1016\/j.seizure.2022.03.024_bib0069","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.fct.2018.05.022","article-title":"Topiramate mitigates 3-nitropropionic acid-induced striatal neurotoxicity via modulation of AMPA receptors","volume":"118","author":"Shalaby","year":"2018","journal-title":"Food Chem Toxicol"},{"issue":"10","key":"10.1016\/j.seizure.2022.03.024_bib0070","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/14656566.2014.915029","article-title":"Pharmacotherapy for tonic-clonic seizures","volume":"15","author":"Rheims","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seizure.2022.03.024_bib0071","article-title":"Topiramate for juvenile myoclonic epilepsy","volume":"11","author":"Liu","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0072","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/epi.13639","article-title":"Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome","volume":"58","author":"Ishii","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0073","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","article-title":"Treatment strategies for dravet syndrome","volume":"32","author":"Knupp","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2022.03.024_bib0074","article-title":"Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis","author":"Zhang","year":"2021","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2022.03.024_bib0075","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neurol.2021.06.004","article-title":"Relationships between migraine and epilepsy: pathophysiological mechanisms and clinical implications","volume":"177","author":"Demarquay","year":"2021","journal-title":"Rev Neurol (Paris"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0076","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eplepsyres.2013.12.013","article-title":"Comorbidity between headache and epilepsy in a Chinese epileptic center","volume":"108","author":"Wang","year":"2014","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0077","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of epilepsy: current concepts and future perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0078","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s10194-020-1074-0","article-title":"The epidemiology of headaches among patients with epilepsy: a systematic review and meta-analysis","volume":"21","author":"Duko","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/j.seizure.2022.03.024_bib0079","doi-asserted-by":"crossref","DOI":"10.21037\/apm-19-690","article-title":"A conjoint analysis of epilepsy and migraine through network-and-pathway-based method","author":"Shu","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2022.03.024_bib0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10072-017-2902-0","article-title":"Shared mechanisms of epilepsy, migraine and affective disorders","volume":"38","author":"Zarcone","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.seizure.2022.03.024_bib0081","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neulet.2017.11.025","article-title":"Pathophysiological mechanisms of migraine and epilepsy: similarities and differences","volume":"667","author":"Mantegazza","year":"2018","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0082","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.gendis.2018.04.007","article-title":"Epilepsy and migraine-are they comorbidity?","volume":"5","author":"Liao","year":"2018","journal-title":"Genes Dis"},{"issue":"11\u201312","key":"10.1016\/j.seizure.2022.03.024_bib0083","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1177\/03331024211017882","article-title":"Dysregulation of the peripheral glutamatergic system: a key player in migraine pathogenesis?","volume":"41","author":"Benbow","year":"2021","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/j.seizure.2022.03.024_bib0084","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamaneurol.2019.0447","article-title":"Antiepileptic drug treatment patterns in women of childbearing age with epilepsy","volume":"76","author":"Kim","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0085","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy","volume":"11","author":"Ben-Menachem","year":"2003","journal-title":"Obes Res"},{"issue":"7","key":"10.1016\/j.seizure.2022.03.024_bib0086","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0149-2918(08)80045-8","article-title":"Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy","volume":"30","author":"Ben-Menachem","year":"2008","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0087","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: a review","volume":"95","author":"Verrotti","year":"2011","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0088","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1517\/13543776.2013.790957","article-title":"Antiobesity carbonic anhydrase inhibitors: a literature and patent review","volume":"23","author":"Scozzafava","year":"2013","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0089","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.pediatrneurol.2014.05.001","article-title":"The effect of topiramate on body weight and ghrelin, leptin, and neuropeptide-Y levels of prepubertal children with epilepsy","volume":"51","author":"Ozcelik","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"Pt A","key":"10.1016\/j.seizure.2022.03.024_bib0090","article-title":"Initiating antiepilepsy treatment: an update of expert consensus in Spain","volume":"114","author":"Villanueva","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0091","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40360-019-0285-y","article-title":"Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015","volume":"20","author":"Du","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"issue":"42","key":"10.1016\/j.seizure.2022.03.024_bib0092","doi-asserted-by":"crossref","first-page":"e22669","DOI":"10.1097\/MD.0000000000022669","article-title":"Topiramate-related adverse events: pattern and signals in the Korea adverse event reporting system, 2010-2017","volume":"99","author":"Choi","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0093","first-page":"130","article-title":"Acute narrow-angle glaucoma induced by topiramate with acute myopia and macular striae: a case report","volume":"94","author":"Sierra-Rodriguez","year":"2019","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0094","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/bcp.12283","article-title":"Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review","volume":"77","author":"Dell'Orto","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2022.03.024_bib0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/21548331.2017.1370969","article-title":"Topiramate and metabolic acidosis: an evolving story","volume":"45","author":"Gupta","year":"2017","journal-title":"Hosp Pract (1995"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.024_bib0096","first-page":"181","article-title":"Psychiatric effects of antiepileptic drugs in adults","volume":"16","author":"Dussaule","year":"2018","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0097","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","article-title":"Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy","volume":"23","author":"Besag","year":"2021","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.seizure.2022.03.024_bib0098","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yebeh.2016.03.013","article-title":"Altered cerebral activity associated with topiramate and its withdrawal in patients with epilepsy with language impairment: an fMRI study using the verb generation task","volume":"59","author":"Tang","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2022.03.024_bib0099","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eplepsyres.2012.12.007","article-title":"The effect of topiramate on cognitive fMRI","volume":"105","author":"Yasuda","year":"2013","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yebeh.2012.02.022","article-title":"Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy","volume":"24","author":"Szaflarski","year":"2012","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.seizure.2022.03.024_bib0101","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1734-1140(13)71473-7","article-title":"Effect of topiramate on hippocampus-dependent spatial memory in rats","volume":"65","author":"Pietrzak","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.024_bib0102","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.braindev.2017.01.006","article-title":"Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy","volume":"39","author":"Moavero","year":"2017","journal-title":"Brain Dev"},{"issue":"4","key":"10.1016\/j.seizure.2022.03.024_bib0103","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.amjmed.2003.08.021","article-title":"Topiramate-induced renal tubular acidosis","volume":"116","author":"Izzedine","year":"2004","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.seizure.2022.03.024_bib0104","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2125.2009.03521.x","article-title":"Effect of topiramate on acid-base balance: extent, mechanism and effects","volume":"68","author":"Mirza","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/FTD.0000000000000461","article-title":"Influence of renal function on pharmacokinetics of antiepileptic drugs metabolized by CYP3A4 in a patient with renal impairment","volume":"40","author":"Yamamoto","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0106","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.06.004","article-title":"Long-term retention rate of topiramate as initial monotherapy in Chinese patients with newly diagnosed epilepsy: a prospective, observational study","volume":"90","author":"Hu","year":"2010","journal-title":"Epilepsy Res"},{"issue":"Suppl 2","key":"10.1016\/j.seizure.2022.03.024_bib0107","first-page":"S90","article-title":"Precision medicine and therapies of the future","volume":"62","author":"Sisodiya","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.03.024_bib0108","article-title":"Novel treatments in epilepsy guided by genetic diagnosis","author":"Marini","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2022.03.024_bib0109","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.753753","article-title":"New trends and most promising therapeutic strategies for epilepsy treatment","volume":"12","author":"Riva","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2022.03.024_bib0110","article-title":"Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases","author":"Parambi","year":"2021","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10.1016\/j.seizure.2022.03.024_bib0111","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/brain\/awaa045","article-title":"In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy","volume":"143","author":"Colasante","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.seizure.2022.03.024_bib0112","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1073\/pnas.1814185115","article-title":"Human induced pluripotent stem cell-derived MGE cell grafting after status epilepticus attenuates chronic epilepsy and comorbidities via synaptic integration","volume":"116","author":"Upadhya","year":"2019","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122000747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122000747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:59:51Z","timestamp":1761011991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131122000747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":112,"alternative-id":["S1059131122000747"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2022.03.024","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms of topiramate and its clinical value in epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2022.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}